| 生物活性 | Cusatuzumab (ARGX-110) is a humanized IgG1 monoclonal antibody targeting CD70 that acts as a selective competitive blocker binding human CD70 with an equilibrium dissociation constant of 17 pM, is synthesized by humanization and genetic engineering (CH2 region mutation to enhance effector function), possesses enhanced antibody-dependent cellular cytotoxicity (ADCC) activity, and exerts dual modes of action: first, it competitively blocks the interaction between CD70 and CD27, inhibits the CD27-NF-κB signaling pathway, and reduces regulatory T cell (Treg) activation and tumor cell proliferation; second, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP) to directly lyse CD70-positive tumor cells; furthermore, Cusatuzumab can efficiently eliminate leukemia stem cells (LSC), induce tumor cell differentiation and apoptosis, restore immune surveillance, target CD70-positive tumors, and is applicable for acute myeloid leukemia (AML) research. | |||||||||||||||||||||||||||||||||||||||||||||
| IC50 & Target | TNFSF7/CD27L/CD70 |
|||||||||||||||||||||||||||||||||||||||||||||
| 体外研究 (In Vitro) |
Cusatuzumab (3-100 nM) 能够以 17 pM 的平衡解离常数特异性结合人 CD70,不结合 CD70 阴性细胞 (SUP-T1、未转染 CD70 的 HEK293),与 FcγRIIIa 的结合能力比岩藻糖修饰版高 70 倍。 Apoptosis Analysis
|
|||||||||||||||||||||||||||||||||||||||||||||
| 体内研究 (In Vivo) |
Cusatuzumab 的岩藻糖修饰版本 41D12 (0.1 mg/kg 及以上;腹腔注射;每周两次;共 5 次) 在 SCID 小鼠 Burkitt 淋巴瘤 Raji 异种移植模型中,可显著延长小鼠存活时间,而肿瘤荷瘤小鼠血清 sCD27 水平高于无肿瘤小鼠。
|
|||||||||||||||||||||||||||||||||||||||||||||
| Clinical Trial |
|
|||||||||||||||||||||||||||||||||||||||||||||
| 性状 | 液体 | |||||||||||||||||||||||||||||||||||||||||||||
| 颜色 | Colorless to light yellow |
| CAS No. | 1864871-20-4 |
| 别名 | 古妥珠单抗; ARGX-110 |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
| 运输条件 | Shipping with dry ice. |
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。